+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bet Inhibitor"

BET inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

BET inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028 - Product Thumbnail Image

Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028

  • Report
  • June 2022
  • 1500 Pages
  • Global
From
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • May 2022
  • 65 Pages
  • Global
From
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2018 - Product Thumbnail Image

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2018

  • Drug Pipelines
  • June 2018
  • 123 Pages
  • Global
From
Precision Cancer Therapies, Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Edition No. 1 - Product Thumbnail Image

Precision Cancer Therapies, Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Edition No. 1

  • Book
  • May 2023
  • 512 Pages
  • 5 Results (Page 1 of 1)
Loading Indicator

The Bet Inhibitor market within the context of Oncology Drugs is a rapidly growing field of research and development. Bet Inhibitors are a class of drugs that target the bromodomain and extra-terminal (BET) family of proteins, which are involved in the regulation of gene expression. These drugs are being studied for their potential to treat a variety of cancers, including leukemia, lymphoma, and solid tumors. Bet Inhibitors work by blocking the activity of BET proteins, which can lead to the inhibition of cancer cell growth and proliferation. In addition, these drugs may also be used to target epigenetic changes associated with cancer, such as DNA methylation and histone modifications. The Bet Inhibitor market is highly competitive, with many companies developing and marketing these drugs. Some of the major players in the market include Merck, Pfizer, Novartis, AstraZeneca, and GlaxoSmithKline. Other companies, such as AbbVie, Celgene, and Bristol-Myers Squibb, are also actively involved in the development of Bet Inhibitors. Show Less Read more